Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Background: MM inevitably relapses and becomes refractory to treatment, representing a patient (pt) population with unmet needs. Teclistamab (JNJ-64007957) is a bispecific BCMA x CD3 antibody that induces T cell-mediated cytotoxicity against BCMA-expressing MM cells. Previously presented results from an ongoing study of teclistamab in RRMM (NCT03145181) included a 67% objective response rate [ORR] for the 270 µg/kg dose administered intravenously (iv) (Usmani et al, ASCO 2020 Oral Presentation #100). Here we present updated results and newly available data for subcutaneous (sc) administration.
Conclusions: Teclistamab has a manageable safety profile, which includes low-grade CRS (with no gr ≥3 events) and low severe infection and neurotoxicity rates with both iv and sc administration. Deep and durable responses were observed with both iv and sc administration. The encouraging tolerability and efficacy of teclistamab support the planned phase 2 monotherapy (at 1500 µg/kg sc) trial and future combination studies.
Please subscribe to our channel!
Subscribe to International Myeloma Foundation: bit.ly/XlUtPE
Visit our website at: www.myeloma.org
Find us online:
Facebook: / myeloma
Google+: gplus.to/imfmyeloma
IMF on twitter: @IMFMyeloma ( / imfmyeloma )
Dr. Durie on twitter: @BrianDurieMD ( / brianduriemd )
Support the IMF! bit.ly/WskQHC
Category
Nonprofits & Activism
License
Standard KZread License